📊 INSP Key Takeaways
Is INSP a Good Investment? Thesis Analysis
Inspire Medical demonstrates exceptional fundamental strength with 85.4% gross margins, accelerating profitability (net income +171.8% YoY despite modest 13.6% revenue growth), and fortress balance sheet (6.08x current ratio, 0.03x debt/equity). The significant operating leverage improvement and strong free cash flow generation ($78.5M, 8.6% FCF margin) indicate a maturing business model transitioning to sustained profitability.
Why Buy INSP? Key Strengths
- Exceptional gross margin of 85.4% demonstrates strong pricing power and efficient manufacturing in medical device sector
- Dramatic net income growth of 171.8% YoY with EPS up 179.4% shows improving operational efficiency and operating leverage
- Fortress balance sheet with $104.8M cash, minimal debt (0.03x D/E), and 6.08x current ratio provides strategic flexibility
- Robust free cash flow generation of $78.5M with positive conversion from operating cash flow
- High ROE of 18.6% and ROA of 16.0% indicate efficient capital deployment and management execution
- Significant insider buying activity with 23 Form 4 filings in last 90 days signals management confidence
INSP Investment Risks to Consider
- Operating margin of only 5.6% despite 85.4% gross margin suggests elevated SG&A and R&D spending that may limit near-term profitability gains
- Revenue growth of 13.6% YoY appears to be moderating, raising questions about market saturation or competitive pressures in surgical sleep apnea market
- Medical device sector faces inherent regulatory risks, reimbursement pressures, and potential for disruptive competitive technologies
- Heavy reliance on single indication (sleep apnea) creates concentration risk despite strong current market position
Key Metrics to Watch
- Revenue growth trajectory and market penetration rates in core sleep apnea procedure volume
- Operating margin expansion as business scales and fixed costs are absorbed
- Free cash flow sustainability and capital allocation decisions (dividends, buybacks, acquisitions)
- Gross margin stability amid potential pricing pressure or unfavorable reimbursement changes
- R&D pipeline success and potential for label expansions or new indications to drive future growth
INSP Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 6.08x current ratio provides a solid financial cushion.
INSP Profitability Ratios
INSP vs Healthcare Sector
How Inspire Medical Systems, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is INSP Overvalued or Undervalued?
Based on fundamental analysis, Inspire Medical Systems, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
INSP Balance Sheet & Liquidity
INSP 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Inspire Medical Systems, Inc.'s revenue has grown significantly by 291% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.72 indicates the company is currently unprofitable.
INSP Growth Metrics (YoY)
INSP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $203.2M | $3.0M | $0.31 |
| Q2 2025 | $195.9M | -$212.0K | $-0.01 |
| Q1 2025 | $164.0M | $3.0M | $0.10 |
| Q3 2024 | $153.3M | -$8.5M | $-0.29 |
| Q2 2024 | $151.1M | -$212.0K | $-0.01 |
| Q1 2024 | $127.9M | -$10.0M | $-0.34 |
| Q3 2023 | $109.2M | -$8.5M | $-0.29 |
| Q2 2023 | $91.4M | -$12.0M | $-0.41 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
INSP Capital Allocation
INSP SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Inspire Medical Systems, Inc. (CIK: 0001609550)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INSP
What is the AI rating for INSP?
Inspire Medical Systems, Inc. (INSP) has an AI rating of STRONG BUY with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are INSP's key strengths?
Claude: Exceptional gross margin of 85.4% demonstrates strong pricing power and efficient manufacturing in medical device sector. Dramatic net income growth of 171.8% YoY with EPS up 179.4% shows improving operational efficiency and operating leverage.
What are the risks of investing in INSP?
Claude: Operating margin of only 5.6% despite 85.4% gross margin suggests elevated SG&A and R&D spending that may limit near-term profitability gains. Revenue growth of 13.6% YoY appears to be moderating, raising questions about market saturation or competitive pressures in surgical sleep apnea market.
What is INSP's revenue and growth?
Inspire Medical Systems, Inc. reported revenue of $912.0M.
Does INSP pay dividends?
Inspire Medical Systems, Inc. does not currently pay dividends.
Where can I find INSP SEC filings?
Official SEC filings for Inspire Medical Systems, Inc. (CIK: 0001609550) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INSP's EPS?
Inspire Medical Systems, Inc. has a diluted EPS of $4.89.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INSP a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Inspire Medical Systems, Inc. has a STRONG BUY rating with 88% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is INSP stock overvalued or undervalued?
Valuation metrics for INSP: ROE of 18.6% (sector avg: 15%), net margin of 15.9% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy INSP stock in 2026?
Our dual AI analysis gives Inspire Medical Systems, Inc. a combined STRONG BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is INSP's free cash flow?
Inspire Medical Systems, Inc.'s operating cash flow is $117.0M, with capital expenditures of $38.5M. FCF margin is 8.6%.
How does INSP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 15.9% (avg: 12%), ROE 18.6% (avg: 15%), current ratio 6.08 (avg: 2).